EUVIMED · CrossrefJournal
Drug Science, Policy and Law
ISSN 2050-3245 · SAGE Publications
Latest articles
The anatomy of distributed risk: ‘Looksmaxxing’, peptides and the limits of information
Characterizing the online claims of Oregon's psilocybin service centers
Same-database comparator group, not a single uncontrolled subgroup what would tell phantom specificity, apart from a genuine cocaethylene-suicide risk marker
A coroner's methadone-poisoning verdict is undone by the very tolerance and toxicology evidence meant to contest it, exposing exculpatory recoding in a single-practice mortality
Psychedelic dosing lexicon lets evidentiary camouflage dress speculative ibogaine and DMT ranges in the same numeric clothing as psilocybin and LSD
Coroners’ verdicts of methadone poisoning can be misleading: A comparison of coronial verdicts of patients treated with opiate substitution treatment in general practice with conclusions drawn from the clinical records
Project Twenty21 Australia: Results of a prospective observational study of patients prescribed medicinal cannabis for chronic pain, anxiety and post-traumatic stress disorder
Real-world approaches are superior to RCTs for studying the potential of CBMPs to treat anxiety
Incentive-linked prescribing and preventable medication-related harm: A narrative review
Comparative medico-legal frameworks for psilocybin regulation: A March 2026 update
Corrigendum to “From Prohibited to Prescribed: The Rescheduling of MDMA and Psilocybin in Australia”
Transforming treatment-resistant depression care in Norway: Public health reimbursement for off-label intravenous ketamine
Epistemology, pharmacology, knowledge sources, and legal responsibility for accurate information
Shared characteristics among those who co-ingest cocaine and alcohol prior to death by suicide: An examination of trends within the National Programme on Substance Use Mortality data
The erosion of safer supply programs in Ontario, Canada: A dangerous step backward
Participation in an indigenous Amazonian-led ayahuasca retreat associated with increases in nature relatedness – a pilot study
Characteristics of and 3-month health outcomes for people seeking treatment with prescribed cannabis: Real-world evidence from Project Twenty21
Decriminalization of drug possession in Oregon: Analysis and early lessons
Medicinal cannabis for pain: Real-world data on three-month changes in symptoms and quality of life
Italian psychedelic therapies of the past century: An historical overview
A comparative study of the harms of nitrous oxide and poppers using the MCDA approach
Psychedelic use predicts objective knowledge about climate change via increases in nature relatedness
2019: A year of expansion in psychedelic research, industry, and deregulation
The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985)
Constructing drug effects: A history of set and setting
Khat ( Catha edulis ): A systematic review of evidence and literature pertaining to its harms to UK users and society
Ecstasy, legal highs and designer drug use: A Canadian perspective
Health-related and legal interventions: A comparison of allegedly delinquent and convicted opioid addicts in Austria
Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary
Public policies on the use of drugs in Mexico and Latin America
EUVIMED